Galapagos Keeps Analysts Guessing About Future Plans
As JAK Inhibitor Jyseleca Beats Forecasts
Executive Summary
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.
You may also be interested in...
Ziritaxestat Failure Could Spell End For Gilead/Galapagos Pact
The Galapagos and Gilead partnership has had a tough few months and the failure of ziritaxestat, plus the decision not to develop filgotinib Stateside for rheumatoid arthritis, is calling into question the merits of the whole collaboration for the US biotech.
Gilead Gives Up On Galapagos's Filgotinib In RA
A disappointing meeting with the FDA means "we no longer see a viable path to US approval in this indication,” said Gilead CEO Daniel O'Day, as Galapagos assumes sole responsibility for the commercialization of the JAK inhibitor in Europe.
Galapagos Knocked By Knee Osteoarthritis Fail
Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.